JCXH-213

N/A

Report date: 2026/05/12 15:11:21

Base Information

Drug NameJCXH-213
Drug Alias NameJCXH-213
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugate > Ab-tLNPCell and gene therapy > Gene therapy > mRNACell and gene therapy > Gene therapy > LNP +[4] 
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaN/A
Originator CompaniesBeijing GoBroad HospitalImmorna (Hangzhou) Biotechnology Co., Ltd
China Registration ClassN/A

Develop Information

Active CompaniesImmorna (Hangzhou) Biotechnology Co., Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A